{
    "nctId": "NCT04985357",
    "briefTitle": "Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs",
    "officialTitle": "Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer, AML, Multiple Myeloma in Relapse, Carcinoma, Carcinoma, Pancreatic, Carcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Carcinoma Breast, Carcinoma Prostate, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Neuroendocrine, Carcinoma, Small Cell Lung, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Esophagus, Carcinoma Cervix, Carcinoma, Thymic, Carcinoma, Ductal, Carcinoma of the Head and Neck, Carcinoma of the Lip, Carcinoma of the Oral Cavity, Carcinoma of Unknown Primary, Carcinoma of the Skin, Carcinoma of the Anus, Carcinoma of the Larynx, Carcinoma of the Penis, Carcinoma of the Oropharynx, Carcinoma of the Appendix, Carcinoma of the Paranasal Sinus, Carcinoma of the Vulva, Malignant Pleural Effusion, Malignant Ascites, Mesothelioma, Cholangiocarcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 630,
    "primaryOutcomeMeasure": "Best overall response (BOR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Sample collection or biopsy of tumor is clinically indicated as part of SOC\n* Prior to preceding onto therapy for treatment\n\nExclusion Criteria:\n\n* Unable to obtain sufficient sample",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}